Pharmacosmos Group Acquires AbFero Pharmaceuticals, Inc.

Leader in Anemia Acquires All Rights for AbFero’s SP-420 to Advance Iron Chelation Therapies

Pharmacosmos Group, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, today announced the acquisition of AbFero Pharmaceuticals, Inc., a Boston-based, privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload.

Pharmacosmos A/S, through a US subsidiary, will acquire all assets of AbFero Pharmaceuticals under a share purchase agreement for a total consideration of up to $225M when combining upfront payments, regulatory and commercial milestones, and royalties.

Read more about Pharmacosmos Group Acquires Boston Based Clinical Stage AbFero Pharmaceuticals, Inc. .